Drug Type Gene editing |
Synonyms EXG001 |
Target |
Mechanism ZSCAN4 gene stimulants(Zinc finger and SCAN domain-containing protein 4 gene stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyskeratosis Congenita | Preclinical | US | Elixirgen Therapeutics, Inc.Startup | 15 Nov 2022 |
Dyskeratosis Congenita | Preclinical | US | 15 Nov 2022 |